Trials / Conditions / Stage IIIC Melanoma

Stage IIIC Melanoma

22 registered clinical trials studyying Stage IIIC Melanoma.

Status	Trial	Sponsor	Phase
Withdrawn	Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma NCT06190249	James Isaacs, MD	Phase 1
Completed	Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations NCT02296112	Vanderbilt-Ingram Cancer Center	Phase 2
Completed	APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Me NCT02166255	Wake Forest University Health Sciences	Phase 1
Terminated	High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By NCT02203604	CINJRegulatory	Phase 2
Completed	Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic NCT02094872	Yale University	Phase 2
Terminated	Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or NCT01835184	National Cancer Institute (NCI)	Phase 1
Terminated	Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Region NCT01701037	Vanderbilt-Ingram Cancer Center	Phase 2
Completed	Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery NCT01748747	Mayo Clinic	EARLY_Phase 1
Terminated	FDG-PET in Advanced Melanoma NCT02236546	Vanderbilt-Ingram Cancer Center	N/A
Withdrawn	Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma NCT02507076	Albert Einstein College of Medicine	N/A
Terminated	Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery NCT01533948	Roswell Park Cancer Institute	Phase 2
Terminated	Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior NCT01519427	National Cancer Institute (NCI)	Phase 2
Completed	Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma NCT01321437	University of California, Irvine	Phase 2
Terminated	Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma NCT01316692	Vanderbilt-Ingram Cancer Center	Phase 2
Withdrawn	RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surger NCT01216787	National Cancer Institute (NCI)	Phase 2
Completed	Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma NCT01127451	Eisai Inc.	Phase 2
Terminated	Dinaciclib in Treating Patients With Stage III-IV Melanoma NCT01026324	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery NCT00470470	National Cancer Institute (NCI)	Phase 2
Completed	Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma NCT00436605	National Cancer Institute (NCI)	Phase 2
Completed	Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma NCT00089063	National Cancer Institute (NCI)	Phase 2
Completed	Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma NCT00085189	University of Southern California	Phase 2
Completed	Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma NCT00003895	National Cancer Institute (NCI)	Phase 2